F. Grossi
University of Udine
15 Papers
107 Citations
F. Grossi is an academic researcher from University of Udine. The author has contributed to research in topics: Lung cancer & non-small cell lung cancer (NSCLC). The author has an hindex of 10, co-authored 15 publications.
Chat about Author
Papers
The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer
TL;DR: Among new drugs with activity in patients with SCLC brain metastases, camptothecin analog topotecan is one of the most promising with a 52% RR and there is an emerging role for systemic chemotherapy, particularly with the use of new active drugs as part of combined modality treatments.
56
Maintenance chemotherapy in non-small cell lung cancer
TL;DR: The role of chemotherapy in patients with advanced non-smallcell lung cancer (NSCLC) has been established only in the last decade and the duration of the chemotherapeutic treatment is a subject of debate between clinical researchers and newchemotherapy strategies have been investigated, including maintenance chemotherapy.
34
Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB–IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST)
Corrado Boni,Marcello Tiseo,Luca Boni,Elizabeth H. Baldini,F Recchia,C. Barone,F. Grossi,Domenico Germano,E. Matano,G Marini,R. Labianca,F. Di Costanzo,A Bagnulo,C Pennucci,C. Caroti,Manlio Mencoboni,F. Zanelli,Tiziana Prochilo,Mara A. Cafferata,Andrea Ardizzoni +19 more
TL;DR: Evidence of a slight survival superiority of GP-containing regimens over platinum-free N-containing chemotherapy is provided and the addition of a third chemotherapy agent (I) to a standard G-based doublet does not improve treatment outcome.
The combination of etoposide and cisplatin in non-small-cell lung cancer (NSCLC)
TL;DR: Preliminary results are encouraging, indicating a small benefit in favor of the last generation of regimens which might therefore replace PE as 'gold standards' in the treatment of advanced NSCLC.
26
Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer
Andrea Ardizzoni,F. Grossi,T. Scolaro,S Giudici,Franca Foppiano,Luca Boni,L Tixi,M. Cosso,Carlo Mereu,G Battista Ratto,Vito Vitale,R. Rosso +11 more
TL;DR: Induction chemotherapy followed by concurrent daily low-dose cisplatin and thoracic irradiation, in patients with locally advanced NSCLC, is active and feasible with minimal non-haematological toxicity, warranting further testing of this novel chemoradiation strategy.